Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6 Suppl 16
|
| pubmed:dateCreated |
1997-2-25
|
| pubmed:abstractText |
Previously untreated patients with stages IIIA or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration-time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82%. The major toxicity was esophagitis. Nine patients (45%) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0093-7754
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
117-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9007137-Adult,
pubmed-meshheading:9007137-Aged,
pubmed-meshheading:9007137-Aged, 80 and over,
pubmed-meshheading:9007137-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9007137-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9007137-Carboplatin,
pubmed-meshheading:9007137-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:9007137-Combined Modality Therapy,
pubmed-meshheading:9007137-Drug Administration Schedule,
pubmed-meshheading:9007137-Esophagitis,
pubmed-meshheading:9007137-Female,
pubmed-meshheading:9007137-Humans,
pubmed-meshheading:9007137-Lung Neoplasms,
pubmed-meshheading:9007137-Male,
pubmed-meshheading:9007137-Middle Aged,
pubmed-meshheading:9007137-Paclitaxel,
pubmed-meshheading:9007137-Pneumonia,
pubmed-meshheading:9007137-Radiation-Sensitizing Agents,
pubmed-meshheading:9007137-Radiotherapy Dosage,
pubmed-meshheading:9007137-Treatment Outcome
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer.
|
| pubmed:affiliation |
Center for Radiation Oncology, Vanderbilt University Medical School, Nashville, TN 37232-5671, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|